Literature DB >> 24482782

The NIHSS Score and its Components can Predict Cortical Stroke.

E Alton Sartor1, Karen Albright2, Amelia K Boehme3, Miriam M Morales4, Amir Shaban5, James C Grotta6, Sean I Savitz, Sheryl Martin-Schild.   

Abstract

BACKGROUND: Neuroprotective agents have the potential to reduce ischemia to penumbra of the cortex, but are time-sensitive. To quickly determine whether a cortical stroke is present without imaging, we created a scoring system based on the NIH stroke scale (NIHSS) that can accurately predict cortical damage in an acute ischemic stroke (AIS).
METHODS: Patients treated with tPA for AIS were retrospectively assessed through prospectively acquired databases at two stroke centers. Stroke was classified as cortical vs. non-cortical stroke. The total NIHSS score, cortical components (gaze, visual fields, language, and neglect) and cortical score (sum of cortical components) were analyzed for site 1 and then validated for site 2 for sensitivity and positive predictive value (PPV) for a cortical stroke.
RESULTS: An acute infarct was detected in 194/239 (81%) patients at site 1 and 122/174 (70%) at site 2 on diffusion-weighted MRI. Cortical involvement was found in 71% (site 1) and 75% (site 2). The median cortical score was 25% of the total NIHSS score at both sites. NIHSS ≥ 4 had the highest sensitivity; PPV was 90% for any cortical sign with ≥ 2 points. The best combination of sensitivity and PPV was cortical score/NIHSS score ≥10%. DISCUSSION: If a trial targeting cortical stroke required that the cortical score represent at least 10% of the total NIHSS score with no imaging, less than 10% of patients with cortical stroke would be missed and less than 18% of patients would be misclassified as having a cortical stroke.

Entities:  

Keywords:  Acute ischemic stroke; Cortical stroke; Diffusion weighted imaging; Epidemiology; MRI; tPA

Year:  2013        PMID: 24482782      PMCID: PMC3904284     

Source DB:  PubMed          Journal:  J Neurol Disord Stroke


  11 in total

1.  Acute stroke trials: strengthening the underpowered.

Authors:  Anthony J Furlan
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

2.  Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials.

Authors:  Maria Philip; Michael Benatar; Marc Fisher; Sean I Savitz
Journal:  Stroke       Date:  2008-12-12       Impact factor: 7.914

3.  Correlation of aphasia and/or neglect with cortical infarction in a subpopulation of RANTTAS.

Authors:  B B Worrall; E Farace; A E Hillis; R K Hutson; R Wityk; J L Saver; K C Johnston; E C Haley
Journal:  Cerebrovasc Dis       Date:  2001       Impact factor: 2.762

4.  Interrater reliability of the NIH stroke scale.

Authors:  L B Goldstein; C Bertels; J N Davis
Journal:  Arch Neurol       Date:  1989-06

5.  Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.

Authors:  M R Frankel; L B Morgenstern; T Kwiatkowski; M Lu; B C Tilley; J P Broderick; R Libman; S R Levine; T Brott
Journal:  Neurology       Date:  2000-10-10       Impact factor: 9.910

6.  Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial.

Authors: 
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

Review 7.  Neuroprotection for acute stroke: making clinical trials work.

Authors:  K W Muir; D G Grosset
Journal:  Stroke       Date:  1999-01       Impact factor: 7.914

8.  Aphasia and neglect after subcortical stroke. A clinical/cerebral perfusion correlation study.

Authors:  D Perani; G Vallar; S Cappa; C Messa; F Fazio
Journal:  Brain       Date:  1987-10       Impact factor: 13.501

9.  NXY-059 for the treatment of acute ischemic stroke.

Authors:  Ashfaq Shuaib; Kennedy R Lees; Patrick Lyden; James Grotta; Antonio Davalos; Stephen M Davis; Hans-Christoph Diener; Tim Ashwood; Warren W Wasiewski; Ugochi Emeribe
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

Review 10.  Clinical experience with excitatory amino acid antagonist drugs.

Authors:  K W Muir; K R Lees
Journal:  Stroke       Date:  1995-03       Impact factor: 7.914

View more
  4 in total

1.  Safety and Efficacy Analyses of Angioplasty and Stenting for Severe Intracranial Arterial Stenosis: A Single-Center Retrospective Study in China.

Authors:  Rong Yin; Fei Chang; Bo Hong; Xiang-Qun Shi; Guo-Zhen Zhang; Zhao Liu; Zhi-Qiang Zhang; Ya-Xuan Wei; Jian-Min Liu
Journal:  Med Sci Monit       Date:  2015-10-31

2.  Does CYP2C19 polymorphisms affect neurological deterioration in stroke/TIA patients?: A systematic review and meta-analysis of prospective cohort studies.

Authors:  Jiajing Wang; Jie Kuang; Yingping Yi; Chen Peng; Yanqiu Ge; Shujuan Yin; Xiaolin Zhang; Jibiao Chen
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

3.  Evaluation of lipoprotein-associated phospholipase A2, serum amyloid A, and fibrinogen as diagnostic biomarkers for patients with acute cerebral infarction.

Authors:  Liang Tao; Wang ShiChuan; Zhang DeTai; Hu Lihua
Journal:  J Clin Lab Anal       Date:  2019-11-11       Impact factor: 2.352

4.  Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction.

Authors:  You Yu; Lin Wang; Xu Zhu; Ya-Fei Liu; Hai-Ying Ma
Journal:  World J Diabetes       Date:  2021-12-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.